Intrexon | XON - Assets


Intrexon reported $73.16M in Assets for its fiscal quarter ending in June of 2024.





Assets Change Date
Agenus USD 172.69M 13.76M Jun/2026
Alaunos Therapeutics USD 1.88M 1.08M Mar/2026
Amgen USD 95.64B 3.14B Jun/2026
Anika Therapeutics USD 183.47M 4.09M Jun/2026
Arrowhead Research USD 2.11B 156.25M Jun/2026
AstraZeneca USD 115.83B 1.82B Jun/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Gilead Sciences USD 49.36B 6.92B Jun/2026
GlaxoSmithKline GBP 61.74B 1.13B Jun/2026
Heron Therapeutics USD 252.26M 6.05M Jun/2026
Incyte USD 7.87B 533.53M Jun/2026
Intrexon USD 73.16M 77.88M Jun/2024
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
Ligand Pharmaceuticals USD 2.19B 653.77M Jun/2026
MacroGenics USD 345.41M 127.54M Jun/2026
MannKind USD 732.3M 12.1M Jun/2026
Merck USD 129.8B 1.12B Jun/2026
Novartis USD 122.03B 3.5B Jun/2026
Rigel Pharmaceuticals USD 242.53M 35.8M Sep/2025
Roche Holding CHF 98.2B 2.5B Jun/2026
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Thermo Fisher Scientific USD 114.23B 1.06B Sep/2026
Veracyte USD 1.49B 49.97M Jun/2026
Xencor USD 724.96M 11.89M Jun/2026